Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H. Jabbour E, et al. Among authors: cortes je. JAMA Oncol. 2024 Nov 21:e245157. doi: 10.1001/jamaoncol.2024.5157. Online ahead of print. JAMA Oncol. 2024. PMID: 39570620
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding.
Cortes JE, Abruzzese E, Cardonick EH, Hernández-Díaz S, Gutierrez J, Sardegna MS, Torres-Chavez E, Dinatale M, Lerro CC, Gehrke BJ, Shord SS, De Claro RA, Theoret MR, DeMaria PJ, Norsworthy KJ. Cortes JE, et al. Clin Cancer Res. 2024 Sep 3;30(17):3658-3666. doi: 10.1158/1078-0432.CCR-24-0826. Clin Cancer Res. 2024. PMID: 38967550 Review.
Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
Toreli ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, Miranda E, Fechio L, Silva Santos Duarte A, Basso A, Duarte G, Souza Medina S, Pericole F, Benites B, Jones K, Singh H, Farmaha J, Vashisht A, Kolhe R, Mondal AK, Saad STO, de Souza CA, Cortes JE, Pagnano K. Toreli ACM, et al. Among authors: cortes je. Leuk Lymphoma. 2024 Nov;65(11):1706-1715. doi: 10.1080/10428194.2024.2367057. Epub 2024 Jul 5. Leuk Lymphoma. 2024. PMID: 38967518
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. Among authors: cortes je. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Cortes JE, et al. Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16. Leukemia. 2024. PMID: 38755421 Free PMC article. Clinical Trial.
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN.
Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. Cortes JE, et al. Haematologica. 2024 Oct 1;109(10):3251-3260. doi: 10.3324/haematol.2023.283428. Haematologica. 2024. PMID: 38695123 Free PMC article. Clinical Trial.
459 results